BioSpace News Archive

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, announced that members of its management team will participate in the following investor conferences,.

Revolo Biotherapeutics (“Revolo Bio” or the “Company”) today announced that the last patient has completed the twelve-week Phase 2a clinical trial evaluating the safety and efficacy of the company’s immune-resetting drug, ‘1104, in allergic disease.

Rhythm Pharmaceuticals, Inc. announced the publication of interview-based patient and caregiver reported experiences of hunger and quality of life with setmelanotide treatment in Bardet-Biedl syndrome.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) today announced positive safety data from the first cohort of the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED).

bioLytical Laboratories Inc., a global leader in rapid in-vitro medical diagnostics, announced that it has received Health Canada authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test, allowing its immediate entry into the Canadian market.

Daxor Corporation, the global leader in blood volume measurement technology, announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023.

Pliant Therapeutics, Inc. today announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023, in Washington, DC.

Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive results from the second preplanned interim analysis of its Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

Alimera Sciences, Inc. announces a series of strategic transactions bolstering its balance sheet, extending its current term loan facility, and recovering value for common stockholders.

POINT Biopharma Global Inc. today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.